Newsletter Tool

Top 10 M&A targets in biotech

Today's Rundown

Califf's confirmation as FDA chief gives biopharma industry a 'steady hand' at the agency: analyst
Biotech pipeline is outpaced by antibacterial resistance, new BIO report says
The top 10 M&A targets in biotech for 2022
Provider groups scramble to convince lawmakers, CMMI to continue Direct Contracting model
Digital stethoscope maker Tyto Care nabs European approval for its lung sound-identifying AI
ASCO GU: J&J plays up precision therapy approach for Zejula's prostate cancer bid after mixed results
Cytokinetics drug fails late-stage trial testing exercise capacity, as FDA considers nod in heart failure
HHS awards community health centers $55M to expand telehealth access for underserved groups
Veracyte’s prostate cancer genomic test can guide patients to best treatment, study finds
A new SPAC decides to enter murky waters to hunt for biotechs in downsized $75M IPO
Thermo Fisher dishes up $40M for Pennsylvania facility expansion, creating more than 100 jobs
The average nonprofit hospital CEO takes home 8 times more than their hourly workers, Lown Institute finds
Quantum-Si taps founder Rothberg, prolific medtech entrepreneur, as interim CEO
Editor's Corner: Fierce Biotech gets a fierce makeover

Featured Story

Califf's confirmation as FDA chief gives biopharma industry a 'steady hand' at the agency: analyst

By Kevin Dunleavy

By a narrow vote of 50-46, Robert Califf has been confirmed by the Senate to run the FDA. Analysts at RBC Capital Markets applauded the confirmation, saying Califf can bring regulatory stability to the biopharmaceutical industry by providing more consistent messaging.

Biotech pipeline is outpaced by antibacterial resistance, new BIO report says

By Max Bayer

Biotechs do not have the arsenal of antibiotic hopefuls in their pipelines to match the growing threat of antimicrobial resistance, according to a new BIO report published Monday.

The top 10 M&A targets in biotech for 2022

By Annalee Armstrong

All the biopharma world is talking about right now is M&A. Who’s going to buy? How much are they willing to spend? Who’s going to get bought? Here are our predictions.

Provider groups scramble to convince lawmakers, CMMI to continue Direct Contracting model

By Robert King

Providers are making an all-out lobbying effort to convince progressive lawmakers and regulators to keep the Direct Contracting payment model, which some lawmakers say is an effort to privatize traditional Medicare.

Digital stethoscope maker Tyto Care nabs European approval for its lung sound-identifying AI

By Conor Hale

The CE mark covers the web-based software module as a separate medical device.

ASCO GU: J&J plays up precision therapy approach for Zejula's prostate cancer bid after mixed results

By Angus Liu

The cancer drug Zejula carries a broad FDA label for ovarian cancer patients. But in metastatic, castration-resistant prostate cancer, the PARP inhibitor appears to work only for a niche population—and that’s bad news for the drug in its ongoing fight for market supremacy against AstraZeneca and Merck & Co.’s rival Lynparza.

Cytokinetics drug fails late-stage trial testing exercise capacity, as FDA considers nod in heart failure

By Kyle LaHucik

Cytokinetics' heart failure drug omecamtiv mecarbil failed to improve exercise capacity in patients with a certain kind of heart failure in a phase 3 study. The trial is not part of the package that the biotech sent to the FDA for a Nov. 30 decision on the drug.

HHS awards community health centers $55M to expand telehealth access for underserved groups

By Dave Muoio

The new American Rescue Plan funds build on a 6,000% uptick in virtual care services being provided by HRSA-funded community health centers from 2019 to 2020.

Veracyte’s prostate cancer genomic test can guide patients to best treatment, study finds

By Andrea Park

While many companies developing blood tests and genomic analyses for cancer are aiming to improve early diagnosis, most of Veracyte’s tests focus instead on what comes after.

A new SPAC decides to enter murky waters to hunt for biotechs in downsized $75M IPO

By Kyle LaHucik

Genesis Unicorn Capital has landed on the Nasdaq, a whole 12 months after incorporating, with a $75 million Wall Street debut to find a biotech or pharma company.

Thermo Fisher dishes up $40M for Pennsylvania facility expansion, creating more than 100 jobs

By Fraiser Kansteiner

Thermo Fisher, plowing ahead on a $650 million bioprocessing expansion, has unveiled a $40 million upgrade at its single-use technologies facility in Millersburg, Pennsylvania. The site is expected to employ more than 1,000 people once fully renovated in the middle of 2023.

PM Tracker